Equity Research, Broker Reports, and media content on MDxHealth S.A.

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about MDxHealth S.A.
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
  • 07 Oct 19
Cancer - Strategy for affordable care

The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc

Companies: IMM IBAB 0O8G BCART 0QLR RHO5 MRCK 0QXH VSC 0QGJ SANO 0OCQ IPH GSK AZN 0Y6X QGEN 0HL9 0GRZ EJXB 0Q15 ABBV 0HAV 0RIH 0R0T BMYS EXK 0J8Z 0R29 0R34 0K3W NSTGQ 0KCC 0Q1N SGEN 0R0H 12V VNRX XE9

goetzpartners securities Limited
  • 31 Aug 18
Building Momentum

With H1/2018A numbers much in line with our expectations, MDxH is building momentum with sustained growth of its Confirm- and SelectMDx prostrate cancer diagnostics. While ConfirmMDx will continue to be the main driver in the shorter term, SelectMDx looks increasingly like the major value driver. Increasing evidence should supports the clinical and economic benefits of SelectMDx throughout prostate cancer therapy from early diagnosis through longer term treatment management and monitoring; a pot

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 27 Jun 18
Prostate cancer test proves value in pre-biopsy screening

Data published today at the Global Congress on Prostate Cancer demonstrates the potential of the MDxH SelectMDx urine-based test to reduce the need for expensive and complex MRI, as well as to help guide physicians in deciding for and against prostate biopsies in clinical practice. These positive results reinforce our view of SelectMDx as a substantial value driver for MDxHealth. We reiterate our OUTPERFORM recommendation and €9 / share target price.

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 25 Apr 18
Back on track in Q1

Strong growth in both test volumes and revenues reported in Q1 indicates that MDxHealth is back on track after the disappointments of 2017. Following a successful $44m fundraising, topline growth at current levels promises to exceed our previous estimates. The company remains attractive at current levels. We reiterate our OUTPERFORM recommendation and €9 / share target price.

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 19 Mar 18
Prostate diagnostic included in EU guidelines

Announcement today that the prostate cancer liquid biopsy SelectMDx is to be included in the European Urological Association ("EUA") guidelines is clearly good news. Designed to allow the identification of patients with aggressive disease prebiopsy, inclusion of the test in the EUA guidelines should facilitate adoption of the test by physicians and payers across Europe. This is the first of a number of upcoming catalysts for MDxHealth that we highlighted in our recent company update report ( Gro

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 27 Feb 18
Growth in prospect a compelling opportunity

Disappointment especially in H2/2017 hit the shares. MDxHealth's potential in prostate cancer diagnosis remains intact; creating a significant opportunity for investors. Test volumes of marketed diagnostics are growing and should accelerate with a fully installed US salesforce and expanding European distribution network. Broadening US reimbursement and product coding should see ConfirmMDx volumes translate into revenues as payment collection accelerates. Data expected during 2018 supporting the

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 29 Dec 17
Contractual delays drive downgrade

The substantial downgrade in guidance from 45% - 55% to 10% - 15% 2017 top line growth is clearly very disappointing. We believe the decrease largely results from smaller than anticipated sample volumes and delays in a large Medicare-funded ConfirmMDx post-marketing study as well as contractual delays related to the flow of billable cases from one or more of its larger customers with whom it has service agreements. The company will provide a more detailed analysis and hopefully better guidance a

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 31 Oct 17
European distribution deals add momentum

With the agreement now reached with Unilabs, MDxH's SelectMDx will now be widely available across major European markets. A Swiss-based laboratory service provider with over 200 laboratories and imaging facilities in nine countries including the major markets - France, UK, Italy, Scandinavia as well as Switzerland, this distribution agreement appears to be a further endorsement of SelectMDx IVD following the first agreement with the German laboratory group Limbach. With ConfirmMDx now reimbursed

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 08 Sep 17
Fuelled for take off

After a disappointing H1 MDxHealth will have to work hard to achieve its 55%-75% sales growth guidance. With a historically stronger H2, we are confident that it has now assembled all the elements to fuel the growth of its prostate cancer test ConfirmMDx from the H2 / 2017. Included in key clinical guidelines, ConfirmMDx is now reimbursed by >60 public and private payers, as well as the subject of a number of service agreements with substantial US healthcare networks. A near doubling of the sale

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 22 Aug 17
Key milestones reached in H1

MDxHealth has achieved a number of significant milestones in the 1H/2017. The company continues to gain traction for its products amongst key US healthcare providers. It has expanded its product offering through the launches of AssureMDx for bladder and the IVD version of SelectMDx for prostate cancer; an agreement is already in place with a major laboratory service provider to supply the IVD test in Germany. After a positive first four month trading statement in May, we are optimistic that firs

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 28 Apr 17
Exact Sciences collaboration

With products for urological and colon cancers already on the market, MDxHealth and Exact Sciences (NASDAQ: EXAS) have already demonstrated their respective expertise in the development of epigenetic molecular diagnostics. The new five year collaboration announced with Exact will enable MDxHealth to leverage its epigenetic expertise outside its core urological focus, as well as build on a decade long relationship with Exact. Exact's acquisition of key MDxH patents related to Exact's Cologuard co

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 24 Feb 17
Further growth and catalysts in 2017

With FY2016 numbers much in-line with our expectations, MDxHealth is becoming a leader in diagnosis of prostate and other urological cancers. Its lead product ConfirmMDx reducing the need for unnecessary biopsies continues to grow as it is increasingly adopted by US urologists and reimbursed by public and private payers. Its first urine-based biopsy SelectMDx is gaining traction through MDxHealth's existing laboratory and commercial platform. The anticipated launch of an IVD SelectMDx kit for Eu

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 10 Nov 16
All set for launch of bladder cancer test

Results published in the Journal of Urology further highlight the high performance of MDxHealth's bladder cancer test and its potential to allow patients to avoid 77% of the costly, invasive and frequently unnecessary cystoscopies that they are currently subject to. In light of the recent €20m fund-raising, the company appears on track for full US launch of the product in early 2017. With recent Q3 results also in line with our forecasts, we reiterate both our OUTPERFORM recommendation and targe

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 31 Oct 16
Further US reimbursement milestone

MDxHealth announced this morning that it had achieved a further US reimbursement milestone by obtaining a Category I CPT code for its prostate cancer diagnostic ConfirmMDx. This, together with the announcement last week of coverage of the product by the fourth largest US health insurer US Health Care Services Corporation (HCSC), should extend the reimbursement of ConfirmMDx in the US further strengthening the company's established commercial platform and ability to create substantial further val

Companies: MDxHealth S.A.

goetzpartners securities Limited
  • 25 Oct 16
Prostate cancer screening without the needle

MDxHealth has already established a robust commercial platform for cancer diagnostics. Focussed on prostate and bladder cancer, MDxHealth's diagnostic tests relieve the clinical burden on the patient and economic burden on the health provider by reducing the need for the risky, expensive and often unnecessary procedures such as needle biopsies that are regularly performed on patients after a positive primary cancer screen. With sales of its first product growing strongly in the US, the company l

Companies: MDxHealth S.A.

goetzpartners securities Limited

MDxHealth S.A.

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on MDxHealth S.A.. We currently have 15 research reports from 1 professional analysts.

Latest News/RNS

(more news)
Date Source Announcement
27Apr21 06:00 GNW MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings
21Apr21 06:00 GNW MDxHealth Provides Q1-2021 Business Update
15May20 17:00 GNW MDxHealth Completes the Equity Investment by MVM Partners
28Apr20 06:30 GNW MDxHealth Announces its Annual and Extraordinary General Shareholders’ Meetings
28Apr20 06:30 GNW MDxHealth Announces its Annual and Extraordinary General Shareholders’ Meetings
26Feb20 06:00 GNW    MDxHealth Reports Financial Year 2019 Results and Provides Outlook for 2020
02Sep18 12:34 EQS MDxHealth (MDXH-BR): Building Momentum
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    MDxHealth S.A.

  • Providers covering

    MDxHealth S.A.